Search

Background and Aim: The experimental gingivitis model is a well-established method in comparing the chemical antiplaque activity of agents and products. The aim of the present study was to use time in order to achieve an exit level of bleeding on probing (BOP) as the primary outcome variable., Methods: The study was a single blind, randomised four treatment parallel group design employing 76 healthy volunteers. The cohort was accepted into the study proper if they achieved a level of /= 50% BOP. Using the baseline and exit BOP, MGI and plaque, a deterioration rate for each parameter was derived and used as the unit of analysis., Results: There were highly significant treatment differences for all three parameters. Paired analyses revealed chlorhexidine was highly significantly more effective than the other rinses for all three parameters. CPC and triclosan were not different from the control for BOP, but CPC was significantly different from the control for MGI and plaque, and triclosan was different from the control for plaque. There were no differences between the CPC and triclosan rinses., Conclusions: The method achieved the expected result of differentiating between the chlorhexidine and the other rinses. Some modification of the method, primarily to group sizes, should improve specificity. The method has the considerable volunteer appeal of early exit, particularly when allocated to control or low activity treatments for plaque.

The aim of this study was to investigate the ability of Triclosan dentifrices to delay the development of gingivitis during a 21-day period without toothbrushing. Test pastes contained 0.3 per cent Triclosan; seven also contained 0.75 per cent zinc citrate; one other contained 2 per cent Gantrez. Plaque and gingivitis increased significantly (p < 0.001) between day 0 and day 21 in the control group. there was no evidence to reject the assumption of similar efficacy across the seven Triclosan/zinc citrate variants. For the combined Triclosan/zinc citrate groups, statistically significant reductions in plaque formation and in gingivitis relative to the control were recorded. Reductions in plaque and gingival bleeding compared to control for the Triclosan/Gantrez group were not statistically significant, although reductions in gingival indices were. The greater reduction in the Gingival Index of the Triclosan/zinc citrate group was also statistically significantly different from that of the Triclosan/Gantrez group, suggesting that a dentifrice containing the former would have a greater antigingivitis potential than a dentifrice containing the latter.

A double blind, 7-month parallel clinical study was conducted to determine the effect of a dentifrice containing 0.3 per cent Triclosan and 0.75 per cent zinc citrate in a 0.8 per cent sodium monofluorophosphate/silica base on supragingival plaque, gingivitis and supragingival calculus formation, compared to a 0.8 per cent monofluorophosphate/silica control dentifrice. The results of this clinical study demonstrate that the use of the Triclosan/zinc citrate dentifrice over a 7-month period provided a statistically significant and clinically relevant benefit in controlling gingivitis, compared to a control dentifrice. Supragingival plaque and calculus levels were also significantly reduced in comparison to the effects of a control dentifrice.

A double blind, seven month clinical study was conducted to determine the effects of three Triclosan containing test dentifrices on supragingival plaque, gingivitis and supragingival calculus formation compared to a 0.8 per cent monofluorophosphate-silica control dentifrice. Each test dentifrice contained 0.3 per cent Triclosan; additionally one contained 0.75 per cent zinc citrate, the second contained 2 per cent Gantrez and the third contained 5 per cent pyrophosphate. Subjects were assigned to one of the three test groups or to the control group according to random allocation within nine strata. Subjects were evaluated for supragingival plaque and calculus formation and for gingivitis after one, four and seven months' use of the dentifrices. After seven months, the Triclosan/Gantrez and the Triclosan/pyrophosphate dentifrices each provided a statistically significant reduction of approximately 25 per cent in gingival bleeding compared to the control. Neither dentifrice gave statistically significant reductions in supragingival plaque or calculus formation. In contrast, the Triclosan/zinc citrate dentifrice provided statistically significant reductions of 33 per cent in supragingival plaque, 51 per cent in gingival bleeding and 67 per cent in supragingival calculus formation. The reductions in gingival bleeding and calculus formation were statistically superior to those of the Triclosan/Gantrez and the Triclosan/pyrophosphate products. The results demonstrate that use of the Triclosan/zinc citrate dentifrice over a seven month period provided statistically significant and clinically relevant reductions in supragingival plaque and calculus formation, and control of gingivitis as compared to a control dentifrice.